8AYY image
Deposition Date 2022-09-04
Release Date 2022-12-07
Last Version Date 2024-07-24
Entry Detail
PDB ID:
8AYY
Title:
Poliovirus type 3 (strain Saukett) stabilised virus-like particle (PV3 SC8) in complex with GSH and Pleconaril
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.60 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Capsid protein, VP1
Mutations:VP1 T105M, VP1 F132L
Chain IDs:A
Chain Length:300
Number of Molecules:1
Biological Source:Human poliovirus 3
Polymer Type:polypeptide(L)
Molecule:Capsid protein, VP0
Mutations:VP2 L18I, VP2 L215M, VP2 D241E, VP4 T67A
Chain IDs:B
Chain Length:340
Number of Molecules:1
Biological Source:Human poliovirus 3
Polymer Type:polypeptide(L)
Molecule:Capsid protein, VP3
Mutations:VP3 H19Y, VP3 L85F
Chain IDs:C
Chain Length:238
Number of Molecules:1
Biological Source:Human poliovirus 3
Primary Citation
A conserved glutathione binding site in poliovirus is a target for antivirals and vaccine stabilisation.
Commun Biol 5 1293 1293 (2022)
PMID: 36434067 DOI: 10.1038/s42003-022-04252-5

Abstact

Strategies to prevent the recurrence of poliovirus (PV) after eradication may utilise non-infectious, recombinant virus-like particle (VLP) vaccines. Despite clear advantages over inactivated or attenuated virus vaccines, instability of VLPs can compromise their immunogenicity. Glutathione (GSH), an important cellular reducing agent, is a crucial co-factor for the morphogenesis of enteroviruses, including PV. We report cryo-EM structures of GSH bound to PV serotype 3 VLPs showing that it can enhance particle stability. GSH binds the positively charged pocket at the interprotomer interface shown recently to bind GSH in enterovirus F3 and putative antiviral benzene sulphonamide compounds in other enteroviruses. We show, using high-resolution cryo-EM, the binding of a benzene sulphonamide compound with a PV serotype 2 VLP, consistent with antiviral activity through over-stabilizing the interprotomer pocket, preventing the capsid rearrangements necessary for viral infection. Collectively, these results suggest GSH or an analogous tight-binding antiviral offers the potential for stabilizing VLP vaccines.

Legend

Protein

Chemical

Disease

Primary Citation of related structures